Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IκB kinase
- 3 September 2008
- journal article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 135 (2), 173-179
- https://doi.org/10.1007/s00432-008-0461-8
Abstract
Curcumin is a natural polyphenolic derogate extracted from spice turmeric, exhibiting anti-inflammatory and chemopreventive activities. It was described to interact with the signalosome-associated kinases and the proteasome-ubiquitin system, which both are involved in the osteoclastogenesis. Thus, we hypothesized that curcumin could diminish osteoclast differentiation and function. For the experiments considering osteoclast differentiation and resorptional activities, preosteoclasts were cultured for 4 weeks and treated with curcumin at subapoptotic dosages. Derived mature osteoclasts were identified as large, multinucleated cells with expression of tartrate-resistant acid phosphatase activity. Formation of resorption lacunae, a hallmark of osteoclast activity, was quantified using dentine pits and light microscopy. The signaling pathways were examined by ELISA-based methods and by immunoblotting. Both 1 and 10 μM curcumin abrogated osteoclast differentiation (by 56 and 81%) and function (by 56 and 99%) (P < 0.05) dose-dependently. The effects were accompanied by the inhibition of IκB phosphorylation and NF-κB activation. In contrast, subtoxic doses did not have any significant effects on proteasome inhibition. This manuscript is the first report that describes the effects of curcumin toward human osteoclastogenesis, and builds the framework for clinical trials of curcumin in the treatment of cancer-induced lytic bone disease.This publication has 43 references indexed in Scilit:
- Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myelomaEuropean Journal of Haematology, 2008
- Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)Experimental Cell Research, 2008
- Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPKBritish Journal of Haematology, 2007
- The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myelomaLeukemia, 2007
- Bone markers in multiple myelomaEuropean Journal of Cancer, 2006
- Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionBiochemical and Biophysical Research Communications, 2005
- Osteoclast differentiation and activationNature, 2003
- A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and FunctionBiochemical and Biophysical Research Communications, 1999
- Cytotoxicity and cytoprotective activities of natural compounds. The case of curcuminXenobiotica, 1996
- Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factorsNature, 1986